Is Finasteride Intake Associated with Penile Curvature/Peyronie’s Disease? Assessment of Both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) Pharmacovigilance Databases

October 2021 in “ European urology open science ”

Nicolò Schifano, Paolo Capogrosso, Luca Boeri, Ernesto Pozzi, Federico Belladelli, Stefania Chiappini, Fabiana Castiglione, F. Deho’, F. Montorsi, Andrea Salonia, Fabrizio Schifano

Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

We don't know much about this study yet.

View this study on sciencedirect.com →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases

2 citations , May 2022 in “International Journal of Impotence Research”

This pharmacovigilance study found strong disproportionality signals suggesting an association between finasteride and Peyronie's disease-related clinical features, but the evidence does not confirm a causal link.

research Assessing finasteride-associated sexual dysfunction using the FAERS database

24 citations , March 2017 in “Journal of The European Academy of Dermatology and Venereology”

This study reported a significant increase in the reporting of sexual dysfunction associated with finasteride use, especially in individuals aged 31-45.

Multidimensional Assessment of Adverse Events of Finasteride: A Real-World Pharmacovigilance Analysis Based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024

research Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024

March 2025 in “PLoS ONE”

This study examined data from the FDA Adverse Event Reporting System and found that finasteride use is linked with both known and previously unlisted adverse events, such as erectile dysfunction and post-5α reductase inhibitor syndrome, with variations observed by age and sex.

research Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024

August 2024 in “medRxiv (Cold Spring Harbor Laboratory)”

This study found that finasteride use is associated with both known and new adverse events, which vary by gender and age, as well as some events not previously listed in the drug insert.

research Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database

1 citations , August 2024 in “Expert Opinion on Drug Safety”

This study analyzed data from the FDA Adverse Event Reporting System and found that finasteride had the highest reporting frequency and signal strength for drug-induced erectile dysfunction among 734 drugs, with compound preparations posing higher risks than single ingredients.